Helicobacter pylori infection: laboratory diagnosis

Giovanni DI BONAVENTURA, PhD

Università “G. d’Annunzio” di Chieti-PescaraNuovo Polo Farmacia, corpo D, III livello (tel 0871 3554812)Centro Scienze dell’Invecchiamento (Ce.S.I.), V livello (tel 0871 541519)E-mail: gdibonaventura@unich.it

C.I. MEDICINA DI LABORATORIOMICROBIOLOGIA CLINICACL MEDICINA E CHIRURGIA – AA 2014-2015

IntroductionHelicobacter pylori is an important human pathogen involved in the pathogenesis of1:

atrophic gastritis

gastroduodenal ulcer

gastric cancer

MALT lymphoma

idiopathic thrombocytopenic purpura, iron deficiency anemia, vitamin B12 deficiency.

H. pylori is not a commensal organism in that the infection always causes gastric mucosal inflammation and damage.

The basic lesion is progressive mucosal inflammation which may result in preneoplastic atrophic changes.

Although H. pylori vary in virulence (e.g., whether the cag pathogenicity island is present), there is a risk of a significant

clinical outcome as the difference in risk between the least and the most virulent is only approximately twofold.1

Because the rate of progression of the mucosal damage is unpredictable, and the infection is always transmissible, it has

been recommended that whenever an H. pylori infection is found it should be cured unless there are compelling reasons that

would mitigate that choice (e.g., very elderly with extensive comorbid diseases).2

H. pylori infections like other major chronic infectious diseases (i.e., syphilis and tuberculosis) are associated with a long

latent period before presenting clinically. As such, many infections will be discovered during this latent period.

Diagnosis

A number of methods to H. pylori infection have been developed and available.

They are generally grouped as being:

“invasive” meaning that they require gastric tissue or mucus samples collected during gastric endoscopy*:

Rapid urease test (RUT)

Hystology

Culture

Molecular methods

“non-invasive” requiring only blood, breath or stool analysis:

Urea breath test (UBT)

Serology

Fecal antigen test

Molecular methods

* Endoscopy is generally recommended as a primary diagnostic method for: any symptomatic patient 45 years or older any patient with “alarm features”

Invasive DiagnosisRapid Urease Test (RUT)

H. pylori is known for production of abundant urease. Urease enzyme hydrolyses urea to release CO2 and NH3.

RUT is an invasive test in that it requires sampling of the gastric mucosa. The test provides indirect evidence of the infection

by identifying the presence of a non-mammalian enzyme, urease, in or on the gastric mucosa.

The test requires a gastric biopsy that is placed in an semisolid (agar gel) or liquid media containing urea and a pH indicator

(i.e. bromophenol blue, …); bacterial urease hydrolyzes the urea to produce ammonia and carbon dioxide. The ammonia

increases the pH leading to the color change (i.e. phenol red: from yellow to pink or red). Different indicators each with a

potential advantage such as being able to start the reaction at a lower pH such as 5.4 and thus reduce the activity of

contaminating mouth bacteria many of which also contain abundant urease.

The system also comprises an antibiotic to suppress growth of non-H. pylori ureasic microorganisms.

The sensitivity of various RUT tests as primary diagnostic tests is high and has been reported to vary between approximately

80% and 100% and specificity between 97% and 99%.3-6

It has an advantage over serology in that it only detects the presence of an active infection.

Invasive DiagnosisRapid Urease Test (RUT)

There are a number of different commercially available RUT kits that primarily differ depending on the platform (e.g., gel, liquid,

membrane, etc.).

Choice depends on availability and local preference as none has proven to be superior.

A positive reaction can be recorded as soon as the gel changes color. Once a positive reaction has occurred no further reading is

necessary. Most of RUT kits makes available positive tests change color within 20-60 minutes. It is recommended the tests are

reviewed after 24 hours as a low level positive infection may not show until then.

Invasive DiagnosisRapid Urease Test (RUT)

PyloriTek (Serim Inc)

Invasive DiagnosisRapid Urease Test (RUT) – agar medium

HpFast, HpOne (GI Supply Inc)CLOtest (TRI-MED Inc)

Invasive DiagnosisRapid Urease Test (RUT) – liquid medium

BIOHIT HELICOBACTER PYLORI UFT300 (BIOHIT HealthCare Inc.)

Invasive DiagnosisRapid Urease Test (RUT)

As for any enzymatic reaction, one must consider the parameters that affect the reaction.

Number of biopsies

Patients with duodenal ulcer typically have non-atrophic mucosa and H. pylori are especially abundant throughout the antrum. A single sample from the antrum or gastric angle will have a high yield (> 85%; often from 95% to 100%).7

Contrarily, if the patient has atrophic gastritis and large areas of intestinal metaplasia, which contain few H. pylori organisms, two samples - one from the antrum avoiding areas of ulceration and obvious intestinal metaplasia, and one from normal appearing corpus - are sufficient and provide the highest yield. 7

Biopsy size

Antral biopsies sample size do not affect sensitivity and specificity.8 However, because larger forceps also provide more information for histologic examination, the largest forceps that will fit through the insertion channel of the endoscopy should be used. If a truly tiny endoscopy is used, samples for RUT can be taken using either the tiny forceps supplied or by brushing the mucosa and placing the brush in the RUT media.

Time before scoring the test as negative

The decision has to be made (positive vs. negative) within 24 hours. Time to positivity is dependent on kit used, ranging from 5 min to 24 h.

The time the test turns positive (and, therefore, the reaction speed) depends on the concentration of bacteria and the temperature. Most will turn positive within 120 to 180 minutes but it is best to hold those that appear negative for 24 hours.10,11 Positive results after 24 hours are most often false positive (due to presence non-H. pylori urease containing organisms) and should not be used for treatment decisions.12

Warming antral biopsies (37°C vs RT) makes possible rapid diagnosis (within 30 minutes) although not more sensitive.9 This could be useful to confirm results more often before the patient leaves the endoscopic area.

Invasive DiagnosisRapid Urease Test (RUT)

The first requirement is that the biopsy sample must come from a site where the organisms are present. A positive RUT requires approximately 104 H. pylori in the biopsy sample.13 This is generally not a problem as the concentration of H. pylori typically exceeds that minimum.

However, false-negative results can occur:

formalin contamination of biopsy forceps.14

in the presence of intestinal metaplasia or the use of antibiotics, bismuth-containing compounds, or proton pump inhibitors (PPIs) that may reduce the bacterial density.16-18 PPIs use or after bismuth or antibiotic use affects not only RUT (decreasing bacterial load and affecting enzymatic activity) but also histology, urea breath test, and culture. It is recommended to stoptherapy 2 weeks before testing.19 H2-receptor antagonists do not reduce the bacterial density and can be used up to the day of the test.19

after partial gastrectomy probably because of reduced bacterial load often related on the presence of bile.

in patient with recent upper gastrointestinal bleeding, where blood leads to decrease sensitivity of RUT possibly related to the presence of albumin, H. pylori killing factors in human plasma, or blood in gastric lumen.20-23

It is unlikely that a false negative RUT will also be accompanied by histologically uninflamed and normal gastric mucosa. When in doubt and the result is important, it is best to obtain a noninvasive test (urea breath test or stool antigen) after discontinuation of the PPI.

Invasive DiagnosisRapid Urease Test (RUT)

False positive results can also occur if:

other urease containing organisms (Proteus mirabilis, Citrobacter freundii, Klebsiella pneumoniae, Enterobactercloacae and Staphylococcus aureus) are present in sufficient quantity. However, unless the patient has achlorhydria or hypochlorhydria, these organisms are unlikely to be present in sufficient concentration to produce a positive test, unless the RUT substrate lacks an inhibitor of their bacterial growth.

the specimen is kept in contact with the media for a prolonged period, typically longer than 24 hours.24

Invasive DiagnosisRapid Urease Test (RUT)

Clinical interpretation of the RUT results

The RUT is a rapid, cheap and simple test that is used frequently in clinical practice. The RUT is best considered as a screening test and not as the gold standard for H. pylori infection.

The sensitivity of the RUT is not 100% and thus a negative test does not fully exclude the presence of an active infection.25,26 False negative tests are also more frequent than false positive tests.

The interpretation of RUT, like any diagnostic test, depends in part on the pretest probability (PTP) of an infection.

In a patient with a duodenal ulcer (high PTP):

- a single positive RUT would be considered confirmative of the diagnosis

- a negative test would need to confirm by another test such as histology (e.g., no evidence of gastric inflammation).

In an elderly patient undergoing endoscopy for gastro-esophageal reflux disease, one would be hesitant to start therapy based only on the basis of a positive RUT. In the case of normal appearing mucosa, it is recommended to take biopsies for RUT as well as for histology: if the RUT is positive, discarding the histology specimens as unnecessary.27-29 While this may make sense in the presence of a high pretest possibility, it would not be prudent in a patient with non-ulcer dyspepsia where the histologic findings themselves may be important (e.g., presence of atrophic changes, dysplasia, etc.).

Post-therapy assessment (test-of-cure). RUT should not be used as the sole arbiter of the results of H. pylori eradication therapy because the sensitivity of the RUT is not 100%.25,26 In reality, endoscopy is infrequently done for test-of-cure except in patients with lesions where further endoscopic and/or histologic evaluation is needed such as gastric ulcer or after resection of adenomatous polyps. For those patients it is probably most cost effective to rely on histologic examination of antral and corpus biopsies.

Invasive DiagnosisRapid Urease Test (RUT)

Use of the RUT sample for additional purposes

The tissue sample contained in the agar of an RUT test can be further used for another purpose:

for molecular testing for H. pylori;

for the presence of clarithromycin resistance;30

for testing the CYP2C19 genotype of the host, since the sample contains host tissue.31

Invasive DiagnosisHystologic examination

Hematoxylin and eosin (H&E) staining is usually adequate (sensitivity and specificity of 69-93% and 87-90%, respectively): it can directly identify H. pylori in a high magnification field and evaluate the degree of inflammation. However, when a low density of H. pylori and atrophic mucosal change are combined, it becomes difficult to see the organism.

The specificity can be improved 90-100% by using special stains such as modified Giemsa stain, Warthin-Starry silver stain, Genta stain, and immunohistochemical (IHC) stain.32,33

Giemsa stain is the preferred method in many laboratories: it is easy to use, inexpensive, and provides consistent results.34,35

Warthin-Starry silver stain was crucial to the original demonstration of H. pylori, but it is expensive and the results are not always reliable.36

Genta stain has the advantage of visualizing both the inflammatory cells and H. pylori by combining silver, H&E, and Alcian blue stains.37 However, this is technically complex, expensive and time-consuming.

IHC staining is more sensitive than traditional stains, and reliable. The major advantages include shorter screening time and high specificity (it can exclude other similar-shaped organisms, such as H. heilimanii, H. bizzozeroni, Pseudomonas fluorescence).38

However, its use is limited because it is not practical to perform.39 It may be useful:

when classic stains are negative but there is evidence for inflammation at histology;

in settings that can result in atypical (including coccoid) forms, uncultivable and difficult to identify by standard staining (it may mimic bacteria or cell debris): in gastric resection specimens, possibly resulting from hypoxia or other stress conditions, and in patients treated for H. pylori gastritis.40

Fluorescence in situ hybridization (FISH) is another method with high specificity and rapidity, taking 3 h to detect H. pylori.41 A set of peptide nucleic acid (PNA) probes was developed to detect H. pylori and its resistance to clarithromycin.42 However, in a prospective study, its sensitivity was only 80% for a specificity of 93.8%.43

Invasive DiagnosisHystologic examination

Lee & Kim, Ann Transl Med 2015;3(1):10

Invasive DiagnosisHystologic examination: the optimal biopsy site

Despite high histology sensitivity, the site, number, and size of biopsy specimen affect diagnostic accuracy.

Patchy H. pylori colonization can sometimes cause misdiagnosis.

The updated Sydney system recommends that biopsy specimens be taken at five different sites for optimal assessment of both gastritis and H. pylori status:44

A-B: from the lesser and greater curvature of the antrum, both within 2-3 cm from the pylorus;

C: from the lesser curvature of the corpus about 4 cm proximal to the angulus;

D: the middle portion of the greater curvature of the corpus, approximately 8 cm from the cardia;

E: from incisura angularis

Lee & Kim, Ann Transl Med 2015;3(1):10

Invasive DiagnosisHystologic examination: the optimal biopsy site

During chronic H. pylori infection, atrophic gastritis (AG) and intestinal metaplasia (IM) begin in the antrum, where H. pylori is commonly undetectable by either conventional or special staining techniques, because IM and hypochlorhydria are unfavorable environments for bacterial colonization.45 A shift in colonization therefore occurs to the proximal stomach (corpus and fundus) where AG and IM extend to the corpus along the lesser curvature side.

In addition, the low prevalence of H. pylori in antral biopsy specimens of atrophic mucosa may be explained by a patchy distribution of the bacterial infection.

As a result, greater curvature side is a good biopsy site for H. pylori detection in patients with AG and IM.

However, biopsy sampling from the lesser curvature of the corpus is known to be the most sensitive and appropriate for evaluation of gastric atrophy regression after H. pylori eradication therapy.46

AG and IM are considered premalignant lesions of gastric cancer. Thus, the appropriate biopsy site for detecting H. pylori infection in gastric cancer patients is similar to that of AG or IM patients.

Invasive DiagnosisHystologic examination: pros & cons

Advantages:

ability to document H. pylori infection

providing more information about the degree of inflammation and associated pathology, such as, atrophic gastritis, intestinal metaplasia, gastric cancer, or lymphoma 47

more sensitive than other tests in the peptic ulcer bleeding setting 48

more sensitive than RUT in the case of atrophic gastritis and intestinal metaplasia 49 In AG or IM, which are less acidic conditions, the bacteria do not need to activate urease, thus reducing RUT sensitivity. In contrast, Giemsa staining is dependent on the morphology of H. pylori, and therefore it detects H. pylori presence regardless of activity, increasing the sensitivity of this test versus RUT.

Limitations:

high costs

long turnaround time

dependence on the skills of the operator 50

sampling error, since the density of H. pylori can vary at different sites 51

decreased sensitivity in patients taking antisecretory therapy (PPIs)

interobserver variability in assessment, due to subjective interpretation of H. pylori features and classification.52-54

Invasive DiagnosisCulture

H. pylori can be isolated by culture from human gastric biopsy samples, although it should be stated that this is not a routine procedure.

Culture is in fact not routinely used for initial diagnosis - it is not as sensitive as histology and RUT – but is required for susceptibility testing if treatment failure is suspected.

A variety of nonselective and selective media have been proposed for isolation of the organism:

Brucella agar supplemented with 5% horse blood, brain heart infusion agar with 7% horse blood, Chocolate agar, and Wilkins-Chalgrenagar;

antibiotic supplements (vancomycin, 10 mg/L; amphotericin B, 10 mg/L and cefsulodin or trimethoprim, 5 mg/L) are recommended for selective media to facilitate primary isolation.

The organism requires a microaerophilic environment (5%-10% CO2, 80%-90% N2 and 5%-10% O2), and 5 to 7 days of incubation at 37°C, with humidity.

H. pylori growths as grey, translucent colonies with swarming.

Colonies are urease, oxidase, and catalase positive. These characteristics, plus a negative hippurate test will distinguish H. pylori from another enteric organism, Campylobacter jejuni.

Recovery from specimens other than gastric biopsies (stool, saliva, and vomitus) is possible but extremely difficult because of the presence other commensal flora comprising other organisms hampering the growth of H. pylori. 55-57

Invasive DiagnosisCulture

H. pylori culture on sheep blood agar

Gram stain of H. pylori

Invasive DiagnosisCulture

As per Koch’s postulates culture is considered to be the most specific way to establish the H. pylori infection.

The sensitivity of isolation the bacterium has been reported to vary greatly among laboratories because it is very fastidious in nature. Even the experienced laboratories recover the organism from only 50% to 70% of actually infected biopsies.58-60

FALSE NEGATIVE RESULTS

Culture results can be affected by PPIs that, altering the pH, indirectly interfere with H. pylori distribution in the stomach, especially in the antral part where bacteria almost disappear.61

Further, it is established that H. pylori has patchy distribution in the stomach.

Therefore, to avoid false negative results, it is recommended, as is done for RUT:

not to consume these drugs 2 wks prior to endoscopy;62

despite the good results from biopsy taken 2 cm prior to pylorus, it is advisable to collect multiple biopsy specimens:62,63 at least 2 biopsy specimens from the antrum and 1 each specimens from the anterior and posterior corpus. It has been in fact observed that the corpus may be the only site which remains positive naturally or sometimes due to consumption of antisecretory drugs.

High gastritis activity, low bacterial load, alcohol drinking, and use of anti-H2 reduced culture efficacy in infected subjects.64

Invasive/Non Invasive DiagnosisMolecular methods

Molecular methods can be carried out both on gastric biopsies (invasive diagnosis) and stool samples (non invasive diagnosis)

They have the advantage of their rapidity and the limited influence of the transport conditions.

Real-time PCR formats have led to the best results in terms of sensitivity and specificity. Furthermore, they may allow concurrent detection of clarithromycin resistance.65

Another kit, MutaREAL Helicobacter pylori (Immundiagnostik, Bensheim, Germany), appeared on the market. It was tested after DNA extraction with Nucli-Sens magnetic extraction reagents (bioMe´rieux). Sensitivity and specificity were 91 and 93% respectively, compared with culture. Sensitivity and specificity for clarithromycin resistance were 91% and 96%, respectively, compared with the Etest.66

H. pylori cagA and vacA genotypes - predictors of progression of preneoplastic lesions - can be determined by PCR on biopsy specimens by reverse hybridization onto a line probe assay. Infection with both cagA positive and vacA s1m1 strains was associated with progression of gastric precancerous lesions with an OR of 4.80 (95% CI 1.71–13.5) versus infection with cagAnegative ⁄ vacA s2m2 strains.67

The main limitation in detecting H. pylori DNA in feces is the presence of inhibitors of the Taq-polymerase and the scant recovery of DNA suitable for PCR analysis.

Non Invasive DiagnosisUrea breath test: principle

In this test labeled urea (13C or 14C) is orally administered to patient via capsule or a flavored liquid.

13C has become increasingly popular because the non-radioactive isotope is innocuous, while 14C has been completely abandoned due to radioactivity.

The labeled urea then diffuses thru the mucosal gel layer of the gastric epithelia where it is broken down by urease enzyme produced by H. pylori.

The released radioactive 13CO2 or 14CO2 is absorbed by gastric wall, then diffuses in the blood.

Once reached the lungs, the expired air is collected and measured in a scintillation counter or infrared spectrophotometer in order to measure the ratio between the isotope of carbon chosen to mark the urea and the 12C, the most frequent isotope present in nature. It is therefore possible to estimate the gastric urease activity, starting from the assumption that in healthy individuals, there is no urease activity in the stomach.

- UBT is preferably performed in the morning after a 6 hours fasting.

- Procedure: 1. citric acid is administered to slow gastric emptying; 2. an exhaled air sampling baseline is collected; 3. urea is administered to patient; 4. after 30 min at rest (without drinking or eating), an exhaled air sample is collected.

UBT takes advantage of the strong urease activity expressed by H. pylori

Non Invasive DiagnosisUrea breath test: pros & cons

Use of Urea breath test (UBT) is often considered as the gold standard test in the diagnosis of H. pylori infection:68,69

It is highly accurate, producing better results in comparison to many of the other available tests

It is also rapid, simple, innocuous, easy to repeat, reproducible, and economic

It is also particularly suitable in all clinical conditions where endoscopy is not strictly necessary, and to check the success of eradication regimens.

The other advantage is that UBT could be also used in pediatric patients.70

Despite many good features of UBT, it has certain shortcomings also.

A definitive standardization of this test does not exist yet

UBT has been observed with poor sensitivity in patient’s undergone gastric surgery or patients on drugs causing changes in neutral pH of gastric mucosa.

Not clear if UBT values can differentiate patients with gastritis, duodenal ulcer, gastric ulcer and gastric malignancy.71,72

Another important issue with UBT is to decide cutoff point between positive and negative 13C-UBT test.73

Non Invasive DiagnosisUrea breath test: performance

In most of the studies, the sensitivity and specificity of the UBT exceed 90%.74

UBT is used to evaluate eradication therapy after giving anti H. pylori regimens. The sensitivity is quite good in post therapy and it may be explained by the fact that the UBT gives positive results when other biopsy-based tests fail. This is because it allows to analyze the entire stomach, therefore detecting the infection even in cases of moderate colonization or patchy distribution of H. pylori.

However, false positive results due to the presence of other urease producing microorganisms are sometimes expected as it has been established that H. pylori is not the only bacteria colonizing stomach.

On the contrary, PPIs and antibiotics may produce false-negative results as well. Further, metabolically inactive coccoid form of H. pylori present in the stomach will not give the positive UBT.

Non Invasive DiagnosisSerological tests

Several H. pylori antigens are capable of inducing immune response: lipopolysaccharides (LPS), CagA, different urease components, heat shock proteins, catalase.75,76

Currently, detection of antibodies (ie, IgM, IgA, IgG) to H pylori is frequently used to diagnose H pylori infection, due to the ease of specimen collection, single time-point testing, and not affected by therapy (PPIs, bismuth-containing compounds, or antibiotics).

Despite these advantages, serologic testing for antibodies to H pylori should be considered with significant caution.

1. The greatest concern regarding this testing method is the poor positive predictive value (PPV), particularly in developed countries where H pylori endemicity is low (ie, 20%-30%).77,78 Therefore, while a negative serologic result suggests the absence of prior exposure to H pylori, a positive result should be confirmed with a noninvasive test that identifies active Helicobacter pylori infection, such as UBT or SAT.

2. Additionally, the sensitivity and specificity are not satisfactory, ranging from 76%-85% and 79%-90%, respectively:77,79

the host immune response varies from individual to individual, also on duration of exposure and nutritional status

since in niche of the bacterium is a mucosal surface, only modest immune response is expected.

cross antigenicity with other prevalent antigenically related bacteria e.g., Campylobacter etc. in endemic area.

H. pylori is a panmictic bacterium which leads to antigenic variable strains (and different antibody profile) in different geographical areas.80,81

good quality antigen is needed and proper cut off value should be determined in endemic areas.

Non Invasive DiagnosisSerological tests

3. The most important limitation is the inability to differentiate between active or past (cured) H. pylori infection:

basically H. pylori infection is a chronic condition and therefore IgG response predominates, as found in majority of the patients.82

it is difficult to pin point acute infection and IgM response has rarely been reported.

IgG levels often remain for years following resolution of infection.83

ELISA testing is generally used for assessing antibody titers. Immunoblot assay gives better specificity but, as it involves high cost and expertise in interpretation, it is not widely used in clinical laboratory and can be used as confirmatory test.84

Serological tests are useful in supporting the diagnosis of active H pylori infection in those situations (gastric atrophy, bleeding ulcers, MALT lymphoma, therapy) where other noninvasive tests may be falsely negative.85

Non Invasive DiagnosisFecal (stool) antigen test

The advantage of stool antigen test (SAT) is to evaluate the eradication of H. pylori infection. It can be performed 4 weeks after completion of treatment to assess success. It is an alternative to UBT for this purpose.

Stool antigen detection using monoclonal antibody has to be preferred to using polyclonal antibodies, since it gives equivalent diagnosis accuracy (sensitivity and specificity) to UBT,86 both before and after treatment.

Despite all the above observation on performance of antigen detection H. pylori in stool, it has certain disadvantage:

antigen excretion may vary over the time period; concentration antigen could be low therefore giving false-negative results

antigen may degrade while passing through intestine

use of N-acetylcysteine like mucolytic agent may decrease the accuracy of the diagnosis87

cut off titer, difficult to decide

What test should be «gold standard» ?

The choice of diagnostic tests to determine H. pylori infection status depends on the sensitivity, specificity, reproducibility, availability cost, and rapidity of the results.

Unfortunately, none of the currently used methods is able to find all patients truly infected.

One solution is to combine the results of two or more techniques.

PCR may be slightly superior as compared to other diagnostic methods for detection of H. pylori infection and to verify H. pylori eradication after treatment. PCR also provides useful information concerning the presence of genes encoding specific virulence factors and antibiotic resistance. Both sensitivity and specificity of nested PCR has been reported to be 100%.

However, such approaches might increase the possibility of false positive results caused by crossover contamination as well as detection of DNA from dead bacteria.

The low positivity rate of the culture may be due to a low number of organisms, presence of non culturable coccoid forms, absence of microorganisms in the gastric biopsy specimens, loss of viability during transport, fastidious growth requirements or contamination by other bacteria suppressing the growth of H. pylori or antibiotic intake. For these reasons was preferred to compare culture results with results of corresponding samples by the other diagnostic methods.

Although PCR may be used as gold standard, the method to be used should be proposed on the basis of level of available diagnostic facilities.

If endoscopic facility is not available in periphery or underdeveloped regions, diagnosis by SAT using monoclonal antibody based kits may be applied on stool specimens.

In situation where UBT system is available but endoscopic facility is not available then this test should be considered the best option.

Although, serology is often misleading but it may be the best in children where sanitary conditions are satisfactory and prevalence of the infection is low especially in pediatric age group. Therefore, utility of each of the invasive and non-invasive tests are almost equally important depending upon the given clinical situation.

DiagnosisAntibiotic resistance testing

• According to the recommendations of the National Reference Centre for Helicobacter, a biopsy to test resistances should be taken no later than after the first failed treatment, in order to find the best antibiotic combination for the patient.

• The GenoTypeHelicoDR (Hain Lifescience GmbH, Nehren, Germany), a reverse hybridization assay, was also used successfully to simultaneously detect H. pylori and the mutations associated with clarithromycin and levofloxacin resistance of H. pylori.

• Biopsy material itself as well as culture material extracted from it can be used as the starting material.

• The test takes only 5 hours. If an identification directly from the biopsy is requested, a result can be obtained in only 1-3 days and thus saves a significant amount of time.

Pros & cons of diagnostic tests

http://www.mayomedicallaboratories.com/articles/communique/2013/11-hpylori-infection/index.html

References1. Shiotani A, Cen P, Graham DY.. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23:492-501.2. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-643. Calvet X, Sánchez-Delgado J, Montserrat A, et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009;48:1385-91.4. Al-Humayed SM, Ahmed ME, Bello CS, et al. Comparison of 4 laboratory methods for detection of Helicobacter pylori. Saudi Med J 2008;29:530-2.5. Redéen S, Petersson F, Törnkrantz E, et al. Reliability of Diagnostic Tests for Helicobacter pylori Infection. Gastroenterol Res Pract 2011;2011:940650.6. Vaira D, Perna F. How useful is the rapid urease test for evaluating the success of Helicobacter pylori eradication therapy? Nat Clin Pract Gastroenterol Hepatol 2007;4:600-1.7. Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015 Jan;3(1):9.8. Yousfi MM, El-Zimaity HM, Cole RA, et al. Detection of Helicobacter pylori by rapid urease tests: is biopsy size a critical variable? Gastrointest Endosc 1996;43:222-49. Yousfi MM, El-Zimaity HM, Cole RA, et al. Does using a warmer influence the results of rapid urease testing for Helicobacter pylori? Gastrointest Endosc 1996;43:260-110. Osaki T, Mabe K, Hanawa T, et al. Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J Med Microbiol 2008;57:814-9.11. Perna F, Ricci C, Gatta L, et al. Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2005;51:247-54.12. Vaira D, Holton J, Cairns S, et al. Urease testsfor Campylobacter pylori: care in interpretation. J Clin Pathol 1988;41:812-3.13. Mégraud F, et al. Current methods used for the diagnosis of Helicobacter pylori infection. In: Buzás GM. eds. Helicobacter pylori - A Worldwide Perspective 2014. Oak Park: Bentham Science, 2014:234-58.14. Ozaslan E, Koseoglu T, Purnak T, Yildiz A. A forgotten cause of false negative rapid urease test: formalin contamination of the sample. Hepatogastroenterology 2010;57:2. p, preceding table of contents.16. Graham DY, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.17. Graham DY, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003;98:1005-9.18. Forné M, et al. Impact of colloidal bismuth subnitrate in the eradication rates of H. pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. Am J Gastroenterol 1995; 90:718-21.19. Attumi TA, Graham DY. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol 2011;9:373-520. Leung WK, et al. False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood. Am J Gastroenterol 1998;93:1914-8.21. Houghton J, et al. Human plasma is directly bacteriocidal against Helicobacter pylori in vitro, potentially explaining the decreased detection of Helicobacter pylori during acute upper GI bleeding. Gastrointest Endosc 2002;55:11-6.22. Tu TC, et al. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest Endosc 1999;49:302-6.23. Wildner-Christensen M, et al. Diagnosis of Helicobacter pylori in bleeding peptic ulcer patients, evaluation of urea-based tests. Digestion 2002;66:9-13.24. Osaki T, Mabe K, Hanawa T, et al. Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J Med Microbiol 2008;57:814-9.25. Malfertheiner P, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.26. Attumi TA, Graham DY. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol 2011;9:373-5.27. Perna F, et al. Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. Minerva Gastroenterol Dietol 2005;51:247-54 28. Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. Gastroenterol Clin North Am 2000;29:871-8.29. Laine L, et al. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1996;44:523-630. Li Y, Rimbara E, Thirumurthi S, et al. Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis 2012;13:54-9 .31. Furuta T, Sugimoto M, Kodaira C, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol 2014;29:487-93. 32. Laine L, et al. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1997;45:463-7.33. Fallone CA, et al. Hematoxylin and eosin staining of gastric tissue for the detection of Helicobacter pylori. Helicobacter 1997;2:32-5.34. Cha MS. Comparative analysis of histochemical stains about detection of H. pylori in gastric mucosa. Korean J Clin Lab Sci 2007;39:223-30.35. El-Zimaity HM, et al. Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains. Mod Pathol 1998;11:288-91.36. Doglioni C, et al. HpSS: a new silver staining method for Helicobacter pylori. J Clin Pathol 1997;50:461-4.37. Genta RM, et al. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994;25:221-6.38. Jonkers D, et al. Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies. J Infect 1997;35:149-54.39. Ashton-Key M, et al. Detection of Helicobacter pylori in gastric biopsy and resection specimens. J Clin Pathol 1996;49:107-11.40. Aggarwal N, Snyder P, Owens SR. Unusual Helicobacter pylori in gastric resection specimens: an old friend with a new look. Int J Surg Pathol 2011;19:297–302.41. Rüssmann H, Kempf VA, Koletzko S, Heesemann J, Autenrieth IB. Comparison of fluorescent in situ hybridization and conventional culturing for detection of Helicobacter pylori in gastric biopsy specimens. J Clin Microbiol 2001; 39: 304-30842 Cerqueira L, et al. PNA-FISH as a new diagnostic method for the determination of clarithromycin resistance of Helicobacter pylori. BMC Microbiol 2011;11:101.43. Cerqueira L, et al. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013;51:1887–93.44. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.45. Craanen ME, et al. Subtypes of intestinal metaplasia and Helicobacter pylori. Gut 1992;33:597-600.

References46. Sugiyama T, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002;16 Suppl 2:187-90.47. Aydin O, et al. Interobserver variation in histopathological assessment of Helicobacter pylori gastritis. World J Gastroenterol 2003;9:2232-5.48. Choi YJ, et al. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter 2012;17:77-85.49. Yoo JY, et al. Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. J Clin Gastroenterol 2007;41:751-5.50. Dickey W, et al. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996;10:289-93.51. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994;40:342-5.52. Molyneux AJ, Harris MD. Helicobacter pylori in gastric biopsies--should you trust the pathology report? J R Coll Physicians Lond 1993;27:119-20.53. Christensen AH, et al. Observer homogeneity in the histologic diagnosis of Helicobacter pylori. Latent class analysis, kappa coefficient, and repeat frequency. Scand J Gastroenterol 1992;27:933-9.54. Aktepe OC, et al. Five methods for detection of Helicobacter pylori in the Turkish population. World J Gastroenterol 2011;17:5172-6.55. Kim do H, et al. Culture and polymerase chain reaction of Helicobacter pylori from rectal and terminal ileal fluid after polyethylene glycol (colyte) ingestion in healthy adults with positive urea breath test. Korean J Gastroenterol 2010;56:27–32.56. Ndip RN, et al. Culturing Helicobacter pylori from clinical specimens: review of microbiologic methods. J Pediatr Gastroenterol Nutr. 2003 May;36(5):616-22.57. Krajden S, et al. Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori. J Clin Microbiol 1989; 27: 1397-139858. Glupczynski Y. Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. Br Med Bull 1998; 54: 175-18659. Feldman RA, Evans SJ. Accuracy of diagnostic methods used for epidemiological studies of Helicobacter pylori. Aliment Pharmacol Ther 1995; 9 Suppl 2: 21-3160. Grove DI, Koutsouridis G, Cummins AG. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. Pathology 1998; 30: 183-18761. Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet 1991; 337: 1486 62. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-32263. Saez J, et al. Real-time PCR for diagnosing Helicobacter pylori infection in patients with upper gastrointestinal bleeding: comparison with other classical diagnostic methods. J Clin Microbiol 2012; 50: 3233-3237 64. Leszczynska K, et al. Patient factors affecting culture of Helicobacter pylori isolated from gastric mucosal specimens. Adv Med Sci 2010;55:161–6.65. Schmitt BH, et al. PCR detection of clarithromycin-susceptible and –resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol 2013;26:1222–7.66. Agudo S, et al. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. DiagnMicrobiol Infect Dis 2010;67:213–9.67. Gonzalez CA, et al. Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol 2011;106:867–74.68. Graham DY, Klein PD. Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. Gastroenterol Clin North Am 2000; 29: 885-9369. Perri F. Diagnosis of Helicobacter pylori infection: which is the best test? The urea breath test. Dig Liver Dis 2000; 32 Suppl 3: S196-S198.70. Koletzko S. Noninvasive diagnostic tests for Helicobacter pylori infection in children. Can J Gastroenterol 2005; 19: 433-43971. Zagari RM, Pozzato P, Martuzzi C, Fuccio L, Martinelli G, Roda E, Bazzoli F. 13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter 2005; 10: 615-61972. Tseng CA, Wu JY, Pan YS, Yu FJ, Kuo CH, Lu CY, Su YC, Wu DC, Perng DS, Jan CM, Wang WM. Comparison of 13Curea breath test values in gastric cancer, peptic ulcer and gastritis. Hepatogastroenterology 2005; 52: 1636-164073. Gisbert JP, Olivares D, Jimenez I, Pajares JM. Long-term follow-up of 13C-urea breath test results after Helicobacter pylori eradication: frequency and significance of borderline delta13CO2 values. Aliment Pharmacol Ther 2006; 23: 275-28074. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. Aliment Pharmacol Ther 2004; 20: 1001-101775. Figueiredo C, et al. Assessment of Helicobacter pylori vacA and cagA genotypes and host serological response. J Clin Microbiol 2001; 39: 1339-134476. Kimmel B, et al. Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect Immun 2000; 68: 915-92077. Chey WD, Wong BC: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-182578. Go MF: Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16 Suppl 1:3-1579. Loy CT, Irwig LM, Katelaris PH, Talley NJ: Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-114480. Higashi H, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 2002; 99: 14428-1443381. Ng EK, et al. Helicobacter pylori heat shock protein A: serologic responses and genetic diversity. Clin Diagn Lab Immunol 1999; 6: 377-38282. Mitchell HM, et al. Antibody to Campylobacter pylori in families of index children with gastrointestinal illness due to C pylori. Lancet 1987; 2: 681-68283. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48: 287-28984. Nilsson I, Ljungh A, Aleljung P, Wadström T. Immunoblot assay for serodiagnosis of Helicobacter pylori infections. J Clin Microbiol 1997; 35: 427-43285. Malfertheiner P, Megraud F, O’Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-78186. Malfertheiner P, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-66487. Demirtürk L, Yazgan Y, Tarçin O, Ozel M, Diler M, Oncül O, Yildirim S. Does N-acetyl cystein affect the sensitivity and specificity of Helicobacter pylori stool antigen test? Helicobacter 2003; 8: 120-123